Protagonist Therapeutics (PTGX) Common Equity (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Common Equity of $655.5 million for Q1 2026, up 6.63% sequentially from $614.7 million in Q4 2025, and down 4.87% YoY from $689.1 million in Q1 2025.
Protagonist Therapeutics (PTGX) Common Equity (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Common Equity for 12 years, with the latest figure at $655.5 million in Q1 2026.
- Quarterly Common Equity fell 4.87% year-over-year to $655.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $655.5 million (down 4.87% YoY) and the FY2025 annual result came in at $614.7 million, down 8.97% from the prior year.
- Common Equity rose to $655.5 million in Q1 2026 per PTGX's latest filing, from $614.7 million in the prior quarter.
- Over five years, Common Equity peaked at $689.1 million in Q1 2025 and troughed at $215.6 million in Q4 2022.
- A 5-year average of $456.5 million and a median of $531.9 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity slipped 28.37% in 2023, then surged 159.26% in 2024.
- Over 5 years, Common Equity stood at $215.6 million in 2022, then surged by 56.15% to $336.7 million in 2023, then soared by 100.58% to $675.3 million in 2024, then fell by 8.97% to $614.7 million in 2025, then increased by 6.63% to $655.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $655.5 million, $614.7 million, and $645.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 841.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 841.54 Mn |
| Mar 31, 2026 | 655.47 Mn |
| Dec 31, 2025 | 614.71 Mn |
| Sep 30, 2025 | 645.44 Mn |
| Jun 30, 2025 | 668.02 Mn |
| Mar 31, 2025 | 689.05 Mn |
| Dec 31, 2024 | 675.30 Mn |
| Sep 30, 2024 | 531.92 Mn |
| Jun 30, 2024 | 541.32 Mn |
| Mar 31, 2024 | 560.44 Mn |
| Dec 31, 2023 | 336.68 Mn |
| Sep 30, 2023 | 302.15 Mn |
| Jun 30, 2023 | 294.07 Mn |
| Mar 31, 2023 | 216.17 Mn |
| Dec 31, 2022 | 215.61 Mn |
| Sep 30, 2022 | 243.62 Mn |
| Jun 30, 2022 | 267.98 Mn |
| Mar 31, 2022 | 301.78 Mn |
| Dec 31, 2021 | 300.02 Mn |
| Sep 30, 2021 | 329.66 Mn |